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Abstract
Introduction: Literature data suggest that sleep disturbances are prevalent among patients with ankylosing
spondylitis (AS) and have a close correlation with pain. Other studies indicate that sleep disturbances are
constantly accompanied by depression and anxiety in AS, but their interrelations are poorly understood. This study
was designed to evaluate sleep disturbances and their association with demographic variables, pain, disease-
specific variables, functional status, covering depression and anxiety in AS patients.
Methods: The 314 patients with AS and age- and sex-matched controls took part in the study, completed a
battery of questionnaires, and participated in long-term follow-up. Blood samples were taken to measure C-reactive
protein (CRP) and the erythrocyte sedimentation rate (ESR). The association among sleep, pain, disease activity,
functional status, depression, and anxiety were assessed by using Pearson/Spearman correlations and multiple
regression analysis.
Results: The Pittsburgh Sleep Quality Index (PSQI) score of the Chinese version was significantly higher in the AS
group than in the control group (P = 0.020). Of the 314 patients with AS, 184 (58.6%) had a high risk for sleep
disturbances. The PSQI score was associated with age, years of education, ESR, CRP, overall assessment of health,
pain, morning stiffness, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis
Functional Index (BASFI), depression, and anxiety (all P < 0.001), but were not associated with disease duration,
fingertip-to-floor distance, and Bath Ankylosing Spondylitis Metrology Index (BASMI) (P > 0.05). In hierarchic
multiple regression analysis, the medical and psychological variables contributed significantly to the variance in
sleep-disturbances scores, adding an additional 23.9% to the overall R2 beyond that accounted for by demographic
variables (R-square, 8.5%), resulting in a final R2of 42.6%. Multiple stepwise regression analysis revealed that anxiety
was the maximal statistical contribution in predicting sleep disturbances (standardized coefficients, 0.287).
Conclusions: The prevalence of sleep disturbances in AS patients is higher than it is generally thought to be.
Depression, anxiety, nocturnal pain, and total back pain are the major contributors of sleep disturbances in AS.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
disease that affects approximately 0.36% of the Chinese
population [1]. It has a negative effect on all aspects of a
patient’s life: physically, psychologically, and socially.
Sleep disturbances are often reported in rheumatic dis-
eases and are considered to be multifactorial. Some
studies document poor quality of sleep in rheumatoid
arthritis (RA), osteoarthritis (OA), systemic lupus
erythematosus (SLE), fibromyalgia, Sjögren’s syndrome,
and spondyloarthritis (SpA) [2-7]. Currently, the patho-
physiology of sleep disturbances is ill defined, and it is
likely to be underreported by AS patients. One possible
reason for the lack of therapeutic success in sleep dis-
turbances is the very limited research conducted on the
frequency and correlates of sleep disturbances in
patients with AS.
Sleep disturbances reduce an individual’s quality of life
by seriously impairing cognition, mood, and physical
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symptoms of diseases. A cross-sectional study investigat-
ing the effects of sleep deprivation on cognition and
work performance of residents and interns in Korea
reported severe sleep deprivation (average night sleep,
less than 4 hours) was associated with a higher level of
stress, more-frequent attention deficit, and difficulty in
learning [8]. In a very large sample of 5,877 participants
aged between 15 and 54 years, reduced quantity of sleep
seemed to be associated with difficulties in coping with
stressful life events [9]. Sleep also plays an important
role in learning processes and memory consolidation;
poor sleep usually is associated with decreased academic
performance and reduced neurobehavioral functioning
[10]. Moreover, a number of longitudinal studies [11-13]
indicate that insomnia or poor sleep is a risk factor for
major depression and anxiety. Presumably, effects of
poor sleep on cognition and mood are due to reducing
cerebral blood flow and metabolic rate in the thalamus,
prefrontal and parietal cortices, and elevating the activity
of the stress systems (the autonomic sympathoadrenal
system and the hypothalamic-pituitary-adrenal system)
[14,15]. Furthermore, sleep alterations increase the
pathologic significance of any disease and reduce general
well-being [16,17]. Clinical studies reported that sleep
problems are inversely associated with the pain thresh-
old at all sites, suggesting a defect in central pain pro-
cessing [2]. Martin [18] suggested a cause-and-effect
relation between sleep dysfunction, psychological effects,
and musculoskeletal function changes; the greatest effect
of sleep disturbances would be a reduction in high-
intensity physical exercise tolerance. Therefore, poor
sleep could cause a negative impact on exercise and
rehabilitation of AS patients. Few studies have been con-
ducted to explore the relation among sleep and physical
and psychological symptoms.
Although, the prevalence, type, and severity of sleep
complaints in an AS population have been difficult to
judge, it has been reported to occur in 15.4% to 80% of
patients with AS, reflecting divergent definitions of sleep
disturbance and instruments of measure. Hultgren et al.
[19] studied 43 male and 27 female patients with AS,
completed a sleep questionnaire, and the results were
compared with earlier findings in 3,558 persons ran-
domly selected from the general population. Too little
sleep was reported by 80.8% of the female and 50.0% of
the male patients, compared with 28.8% and 21.8%,
respectively, in the reference group. Another study [7]
assessed the sleep quality of patients with spondyloar-
thropathy (SpA) with the PSQI in Canada; 69% of the
sample were classified as poor sleepers, and worse func-
tional status was associated with poorer sleep quality,
longer sleep latency, shorter sleep duration, and poorer
sleep efficiency. A recent study [20] of sleep disturbance,
assessed by the fourth item of the Hamilton anxiety scale,
was found in 15.4% of 110 patients with AS. Although
sleep complaints are commonly reported in rheumatism,
little is known in persons with AS. Moreover, it is unclear
whether the severity of AS is directly related to poor
sleep quality. Specifically, given the considerable adverse
effects of sleep disturbances on clinical outcomes, identi-
fying the factors associated with poor sleep is an impor-
tant goal. Studies addressing this issue have had some
limitations: small sample size, inclusion of patients with
SpA, and lack of comprehensive assessment of sleep
quality and physical and psychological status.
The objective of this study were (1) to determine the
prevalence of sleep disturbances and their association
with demographic variables, disease-specific variables,
and other variables that can have an impact on sleep;
and (2) to evaluate the statistical contribution in predict-
ing sleep disturbances in AS patients.
Methods
For long-term follow-up, patients were recruited from
two rheumatology clinics and departments in the Chinese
PLA General Hospital, and the healthy controls were
recruited from three communities. All patients met the
1984 modified New York classification criteria for AS
[21]. The 102 age- and sex-matched healthy controls (84
men, 18 women) were included in this case-control
study. Controls were group matched by age groups (15 to
20 years, 21 to 25 years, 26 to 30 years, and 30 years and
older), meaning that the proportion of controls in each
age group was identical to the proportion of patients in
each age group. The patients and controls who had
malignancy, fibromyalgia, serious infections or systemic
diseases, and other chronic diseases were excluded from
the study. The study was approved by the Chinese PLA
General Hospital ethics committee, and all participants
gave their written informed consent, according to the
Declaration of Helsinki.
Demographic characteristics, age, years of education,
occupation, marital status, disease duration, and duration
of morning stiffness were documented for each patient.
The patients were subjected to a detailed investigation
including hemogram, liver, and kidney-function tests, to
exclude other diseases that may cause sleep disturbances.
Sleep quality was assessed by using the Chinese version
of the PSQI; depressive symptoms, with Zung self-rating
depression scale (SDS), and anxiety symptoms with the
Zung self-rating anxiety scale (SAS). Overall assessment
of health score in AS patients was determined from a
visual analogue scale (VAS), recording from 0 cm (none)
to 10 cm (very severe); the pain score by visual analogue
scale (VAS, 0 to 10 cm), included nocturnal pain (last
week/spine/at night due to AS) and total back pain (last
week/spine/due to AS). The disease activity was evalu-
ated by the BASDAI, CRP, ESR, and duration of morning
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stiffness; the functional state was assessed by BASFI,
metrologic measurements by fingertip-to-floor distance,
and BASMI. The PSQI, SDS, and SAS were used in
healthy controls to assess sleep, depression, and anxiety
respectively.
Sleep quality
Sleep during the month preceding the evaluation was
examined by using the PSQI, which includes 19 ques-
tions completed by the subject. These 19 items were
broken down into the following seven components: sub-
jective sleep quality, sleep latency, sleep duration, habi-
tual sleep efficiency, sleep disorders, use of hypnotics,
and daytime dysfunction. Sleep latency is assessed by
two questions rated according to time to fall asleep.
Sleep duration by one question rated 4 on a Likert scale
from >7 to <5 hours, and sleep efficiency by hours
asleep divided by total of hours in bed. Use of hypnotics
and poor daytime functioning are rated by a 4-point
Likert scale (not during the past month, less than once
per week, once or twice per week, 3 or more times per
week). Sleep disorders were assessed with nine questions
focused on waking up in the middle of the night or early
in the morning, getting up to go to the toilet, difficulty
breathing properly, coughing or snoring loudly, being
too cold, being too hot, having nightmares, experiencing
pain, or other reasons for disturbed sleep. Each question
is rated with a 4-point Likert scale (not during the past
month, less than once per week, once or twice per
week, 3 or more times per week). Subjective sleep is
evaluated with one question rated by a 4-point Likert
scale from very good to very bad. The seven compo-
nents were each scored from 0 (no difficulty) to 3
(severe difficulty), and summed, to give an overall score
ranging from 0 to 21. Participants were dichotomized
into a poor-sleep group if the PSQI was >7.0 and a
good-sleep group if the PSQI was ≤7.0 [22].
Depressive symptoms
The depression levels of the patients were evaluated by
using the SDS. This scale consists of 20 questions that
examine the somatic, affective, and psychological symp-
toms associated with depression. Each question is scored
between 1 and 4 (rarely, sometimes, frequently, and
always). The total score varies between 20 and 80. Higher
scores reflected more-severe depression. A score of 50 to
69 shows the existence of depression, and a score of 70
or higher means extreme depression [23].
Anxiety symptoms
The revised SAS was used to evaluate the level of anxi-
ety-related symptoms during the last week before the
survey. This self-administered test has 20 questions, with
15 items worded toward increasing anxiety levels and five
questions worded toward decreasing anxiety levels. Each
question was scored on a scale of 1 to 4 (rarely, some-
times, frequently, and always). The scores ranged
between 20 and 80. A score of 50 to 69 shows the exis-
tence of anxiety, and a score of 70 or higher means
extreme anxiety [24].
Data analysis
Descriptive statistics were used for assessing the para-
meters related to disease. The differences in terms of
variables that are studied in patients who are grouped as
experiencing poor sleep and good sleep, according to
the PSQI, were evaluated with independent sample
Mann-Whitney U test and a t test. The relations
between the sleep and the other evaluation parameters
were examined with Spearman rank correlation analysis.
Hierarchic multiple regression analysis was chosen to
analyze the contribution of demographic, medical, and
psychological variables to sleep disturbances. Stepwise
multiple regression analysis was designed to find the
most powerful predictor of sleep disturbances. Statistical
analysis was performed by using SPSS 17.0, and the
level of significance was set at P < 0.05.
Results
Patient characteristics
Of the 318 AS patients who agreed to participate in this
study, 314 (98.7%) returned their completed question-
naires, and four patients were no longer interested and/
or had no time to participate.
Demographic and clinical characteristics of the
patients are given in Table 1. The 314 consecutive
patients with AS (234 men, 80 women) were included in
the study. The mean age of patients was 27.6 ± 8.3
years, and the mean disease duration was 6.1 ± 4.9
years. The mean PSQI, SDS, and SAS scores of patients
were 6.6 ± 3.6, 47.3 ± 10.5, and 48.4 ± 8.1, respectively.
Sleep-disturbances parameters
As shown in Table 2, components of PSQI include sub-
jective sleep quality, sleep latency, sleep duration, habi-
tual sleep efficiency, sleep disorders, use of hypnotics,
and daytime dysfunction. The seven components were
each scored from 0 (no difficulty) to 3 (severe difficulty).
When the score of the components was ≥2, the compo-
nent was regarded as indicating sleep disturbance. We
found that poor subjective sleep quality was 22.3%, sleep
latency was 22.9%, sleep duration was 13.4%, habitual
sleep efficiency was 25.6%, sleep disorders was 30%, use
of hypnotics was 2.9%, and daytime dysfunction was
57.6% in patients with AS. The most prominent sleep
disturbance was daytime dysfunction. Despite the high
incidence of sleep disturbance in AS patients, they rarely
use hypnotics.
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Mann-Whitney U test and t test
The prevalence of poor sleep was 35.4%, and the mean
total PSQI score was 6.62 ± 3.62 in participants, com-
pared with 22.9% and 5.50 ± 2.51, respectively, in the
control group. The total PSQI score of patients with AS
was significantly higher than that of the control partici-
pants (6.62 ± 3.62 versus 5.50 ± 2.51; P = 0.020), and
four of the seven components of PSQI in AS patients
were significantly different from controls: sleep latency,
sleep duration, habitual sleep efficiency, and sleep disor-
ders (see Table 3).
The Mann-Whitney U test and a t test were performed
between patients who were good and poor sleepers (see
Table 4). Poor-sleep patients with had significantly higher
levels of morning stiffness, BASFI, overall poor assessment
of health, nocturnal pain, total back pain, BASDAI, ESR,
CRP, SDS, and SAS (P < 0.05) than did good-sleep
patients. With regard to age, years of education, disease
duration, fingertip-to-floor distance, and BASMI score, no
statistically significant differences were found between the
two groups (P > 0.05)
Bivariate associations
As shown in Table 5, Spearman rank correlation coeffi-
cients were computed to identify correlates of compo-
nents of PSQI, demographic, clinical, and psychogenic
variables in our sample of AS patients. PSQI and almost
all components of the PSQI score were associated with
age, years of education, ESR, CRP, morning stiffness,
overall assessment of health, nocturnal pain, total back
pain. The BASDAI, BASFI, SDS, and SAS (P < 0.001),
were not associated with disease duration, fingertip-to-
floor distance, and BASMI (P > 0.05). In these, sleep
scores was moderately related to depression scores (rho,
0.467), nocturnal pain (rho, 0.487), total back pain (rho,
0.485), BASDAI (rho, 0.479), overall assessment of health
(rho, 0.386), and BASFI (rho, 0.312), and highly related to
anxiety scores (rho, 0.522).
Hierarchic multiple regression analysis
The results of the hierarchic multiple regression ana-
lyses are shown in Table 6.
Model 1 (demographic model) tests the contribution of
demographic variables to sleep disturbances.
Model 2 (medical variables model) tests the contribu-
tions of medical and physiological variables to sleep distur-
bances after controlling for the demographic variables.
Model 3 (psychological model) describes the extent to
which psychological variables contribute to sleep distur-
bances after controlling for the demographic variables.
Models 1 through 3 are the results of hierarchic regression
Table 1 Demographic and disease-related characteristics
of patients with ankylosing spondylitis
Variables Values
Age (years)a 27.65 ± 8.34
Gender: female, n (%)b 80 (25.5)
Years of education, n (%)b
≤6 years 8 (2.5)
7-9 years 54 (17.2)
10-12 years 78 (24.8)
13-17 years 156 (49.7)
≥18 years 8 (5.7)
Number employed, n (%)b 191 (60.8)
Number of students, n (%)b 89 (28.3)
Married, n (%)b 177 (56.4)
ESR (mm/h)a 16.80 ± 18.78
CRP (mg/dl)a 1.62 ± 3.45
Disease duration (years)a 6.07 ± 4.90
Morning stiffness (minutes)a 11.90 ± 27.80
Fingertip-to-floor distance (cm)a 9.77 ± 13.70
Overall assessment of health (VAS)a 5.34 ± 2.87
Nocturnal pain (VAS)a 3.69 ± 2.95
Total back pain (VAS)a 3.85 ± 2.70
BASMIa 1.39 ± 1.89
BASDAI (VAS)a 3.58 ± 2.09
BASFI (VAS)a 1.64 ± 2.17
PSQIa 6.62 ± 3.62
SDSa 47.26 ± 10.45
SASa 48.36 ± 8.10
aMean ± SD. bPercentage. N = 314. BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index;
BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein;
ESR, erythrocyte sedimentation rate; PSQI, Pittsburgh Sleep Quality Index; SAS,
Self-rating Anxiety Scale; SDS, Self-rating Depression Scale; VAS, visual
analogue scale.
Table 2 Descriptive statistics on the components of PSQI in cases
PSQI components score 0 1 2 3
Subjective sleep quality, n (%) 78 (24.8) 166 (52.9) 58 (18.5) 12 (3.8)
Sleep latency, n (%) 103 (32.8) 139 (44.3) 46 (14.6) 26 (8.3)
Sleep duration, n (%) 155 (49.4) 117 (37.3) 31 (9.9) 11 (3.5)
Habitual sleep efficiency, n (%) 136 (43.3) 98 (31.2) 41 (13.1) 39 (12.4)
Sleep disorders, n (%) 39 (12.4) 181 (57.6) 84 (26.8) 10 (3.2)
Use of sleep medications, n (%) 297 (94.6) 8 (2.5) 4 (1.3) 5 (1.6)
Daytime dysfunction, n (%) 35 (11.1) 98 (31.2) 109 (34.7) 72 (22.9)
N = 314.
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analyses, which are usually done in research to determine
the importance of predictor variables once other predictor
variables have already been entered into the equation.
Model 4 is the standard regression analysis in which all
of the variables were entered simultaneously into the
model to assess the relative contributions of these vari-
ables to sleep disturbances. This model takes into
account the interrelations between predictor variables as
well as the effects of predictor variables on the outcome
variable (sleep disturbances). The first model testing the
contributions of demographic variables to sleep distur-
bances was found to be statistically significant (R2 =
0.85). In this model, years of education (P = 0.011) con-
tributed significantly to sleep disturbances. The addition
of medical variables (model 2) resulted in a significant
increase in the R2 value (R2 = 0.32). In this model,
Nocturnal pain (P = 0.012) and BASDAI (P = 0.005) con-
tributed significantly to sleep disturbances. Inclusion of
psychological variables also significantly added to the
demographic set (R2 = 0.324). In this model, SDS (P =
0.004) and SAS (P = 0.000) contributed significantly to
sleep disturbances. The medical and psychological vari-
ables explained an additional 23.9% of the variance in
sleep disturbances. In the final full model (standard mul-
tiple regression analysis), in which all of the variables
were entered simultaneously, only nocturnal pain (P =
0.009), SDS (P = 0.008), and SAS scores (P = 0.000)
remained as significant determinants of sleep distur-
bances. The full model could explain 42.6% of the total
variance in sleep disturbances.
Multiple stepwise regression analysis
The results of the stepwise multiple regression analyses
are shown in Table 7. The SDS score (B = 0.059; P =
0.004), SAS score (B = 0.128; P = 0.000), nocturnal pain
(B = 0.235; P = 0.013), and total back pain (B = 0.210;
P = 0.044) were found to be significantly associated with
sleep disturbances. The R2 = 39.5 indicated that 39.5%
variation of sleep disturbances could be explained by
depression, nocturnal pain, and total back pain. None of
the factors significantly influenced sleep disturbances
(age, gender, years of education, occupation, marital sta-
tus, ESR, CRP, disease duration, morning stiffness, finger-
tip-to-floor distance, BASMI, BASDAI, or BASFI). The
stepwise multiple regression analyses revealed that anxi-
ety was the maximal statistical contribution in predicting
back pain (standardized coefficients of 0.287).
Discussion
The current study is, to our knowledge, the largest to eval-
uate sleep disorders in AS patients. The relation between
sleep disturbances and physical and psychological pro-
blems were described by the following six aspects.
Characteristics of sleep in AS patients
Significant sleep disturbance was much more common in
AS patients than in the control group. PSQI is a standard
index for assessing sleep quality and is widely used in
both clinical settings and public health practice. The pre-
valence of poor sleep was 35.4%, and the mean total
PSQI score was 6.62 ± 3.62 in participants, compared
with 22.9% and 5.50 ± 2.51, respectively, in the control
group. This prevalence was lower than those reported,
54.1% and 64.5% of sleep disturbance, respectively, in
other studies of AS patients [20,25].
Among seven components of PSQI, the most promi-
nent component of sleep disturbances was daytime dys-
function. In total, 57.6% of participants reported various
degrees of daytime dysfunction, including excessive day-
time sleepiness, fatigue, and changes in mood. In another
Table 3 Comparison of the components of PSQI in cases
and controls





Subjective sleep quality 1.01 ± 0.77 0.89 ± 0.79 0.127
Sleep latency 0.98 ± 0.89 0.69 ± 0.88 0.001
Sleep duration 0.68 ± 0.79 1.29 ± 0.86 0.000
Habitual sleep efficiency 0.95 ± 1.03 0.25 ± 0.64 0.000
Sleep disorders 1.21 ± 0.69 0.74 ± 0.63 0.000
Use of sleep medications 0.10 ± 0.46 0.01 ± 0.09 0.055
Daytime dysfunction 1.69 ± 0.95 1.63 ± 1.00 0.635
Total 6.62 ± 3.62 5.50 ± 2.51 0.020
P values were obtained with the Mann-Whitney U test. PSQI, Pittsburgh Sleep
Quality Index.
Table 4 Comparison between poor and good sleepers
(sorted by P value)
Variables PSQI ≤7 PSQI >7 P
n = 203 n = 111
SDS 44.15 ± 9.44 52.95 ± 9.83 0.000
SAS 45.78 ± 7.07 53.07 ± 7.77 0.000
BASDAI 2.98 ± 1.87 4.66 ± 2.03 0.000
BASFI 1.23 ± 1.83 2.39 ± 2.51 0.000
Nocturnal pain (VAS) 2.89 ± 2.64 5.17 ± 2.94 0.000
Total back pain (VAS) 3.12 ± 2.49 5.18 ± 2.57 0.000
Overall assessment of health (VAS) 4.67 ± 2.79 6.59 ± 2.58 0.000
Morning stiffness (minutes) 9.53 ± 26.48 16.24 ± 29.70 0.002
Age (years) 26.83 ± 8.03 29.70 ± 8.59 0.002
ESR (mm/h) 14.51 ± 15.44 20.98 ± 23.21 0.018
CRP (mg/dl) 1.32 ± 1.65 2.16 ± 5.33 0.039
Years of education 4.46 ± 0.89 4.25 ± 0.98 0.058
BASMI 1.29 ± 1.87 1.59 ± 1.93 0.069
Disease duration (years) 5.70 ± 4.57 6.74 ± 5.40 0.116
Fingertip-to-floor distance (cm) 9.65 ± 13.51 9.99 ± 14.09 0.859
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis
Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate;
PSQI, Pittsburgh Sleep Quality Index; SAS, Self-rating Anxiety Scale; SDS, Self-
rating Depression Scale; VAS, visual analogue scale.
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Table 5 Correlation coefficients between components of PSQI, demographic, clinical, and psychogenic variables
(Spearman rho)














Age (years) 0.165** 0.073 0.142* 0.074 0.065 0.193** 0.135* 0.139*
Years of education -0.149** 0.003 -0.206** -0.083 -0.119* -0.047 -0.186** -0.099
ESR (mm/h) 0.163** 0.187** 0.086 0.070 0.171** 0.102 0.062 0.044
CRP (mg/dl) 0.164** 0.172** 0.072 0.034 0.159** 0.134* 0.040 0.125*
Disease duration (years) 0.094 0.051 0.091 0.011 -0.013 0.095 -0.014 0.133*
Morning stiffness
(minutes)
0.250** 0.219** 0.185** 0.103 0.177** 0.173** 0.069 0.180**
Fingertip-to-floor
distance (cm)
0.04 0.040 0.010 -0.038 -0.025 0.084 0.049 0.114*
Overall assessment of
health (VAS)
0.386** 0.258** 0.241** 0.073 0.200** 0.359** 0.174** 0.375**
Nocturnal pain (VAS) 0.487** 0.324** 0.337** 0.181** 0.330** 0.364** 0.129* 0.388**
Total back pain (VAS) 0.485** 0.319** 0.297** 0.199** 0.295** 0.386** 0.176** 0.424**
BASMI 0.093 0.044 0.057 0.023 0.105 0.122* 0.025 0.065
BASDAI 0.479** 0.322** 0.327** 0.130** 0.214** 0.421** 0.206** 0.467**
BASFI 0.312** 0.198** 0.168** 0.052 0.119* 0.421** 0.128* 0.313**
SDS 0.467** 0.290** 0.346** 0.124* 0.178** 0.438** 0.167** 0.448**
SAS 0.522** 0.347** 0.384** 0.173** 0.236** 0.493** 0.169** 0.439**
*P < 0.05; **P < 0.01. Spearman rho, <0.3, the weak correlation; Spearman rho, 0.3 to 0.5, the medium correlation; Spearman rho, >0.5, the high correlation.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology
Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PSQI, Pittsburgh Sleep Quality Index; SAS, Self-rating Anxiety Scale; SDS, Self-rating Depression
Scale; VAS, visual analogue scale.
Table 6 Hierarchic multiple regression analysis of demographic, medical, and psychological variables in relation to
PSQI
Model 1 Model 2 Model 3 Model 4
B P value B P value B P value B P value
Age (years) 0.057 0.122 0.064 0.081 0.032 0.314 0.055 0.103
Gender (male) 0.738 0.108 0.098 0.823 -0.228 0.575 -0.435 0.292
Years of education -0.583 0.011 -0.333 0.105 -0.266 0.181 -0.190 0.318
Student (yes) -1.261 0.083 0.587 0.365 -0.805 0.203 -0.455 0.449
Employment (yes) -1.068 0.078 -1.099 0.043 -0.638 0.225 -0.798 0.112
Married (yes) 0.174 0.788 0.168 0.769 0.010 0.985 0.011 0.984
ESR 0.007 0.535 0.009 0.399
CRP -0.005 0.941 -0.022 0.706
Disease duration -0.055 0.230 -0.052 0.214
Morning stiffness (minute) 0.001 0.919 0.001 0.904
Fingertip-to-floor distance (cm) -0.011 0.481 -0.009 0.531
Overall assessment of health (VAS) 0.029 0.760 -0.039 0.658
Nocturnal pain (VAS) 0.267 0.012 0.258 0.009
Total back pain (VAS) 0.133 0.302 0.168 0.159
BASMI -0.222 0.100 -0.149 0.233
BASDAI (VAS) 0.456 0.005 0.210 0.168
BASFI (VAS) -0.067 0.595 -0.157 0.184
SDS 0.064 0.004 0.059 0.008
SAS 0.170 0.000 0.120 0.000
R2 (%) 8.5 32.0 32.4 42.6
Adjusted R2 (%) 6.7 28.0 30.6 38.9
Model 1 F = 4.756; P = 0.000; Model 2 F = 8.176; P = 0.000; Model 3 F = 18.290; P = 0.000; Model 4 F = 11.507; P = 0.000. BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; PSQI, Pittsburgh Sleep Quality Index; SAS, Self-rating Anxiety Scale; SDS, Self-rating Depression Scale; VAS, visual analogue scale.
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study in patients with AS [20], 66.4% experienced severe
fatigue, and a positive relation was established between
fatigue and sleep problems. These changes are reflected
in patient reports of difficulty in concentrating, increased
forgetfulness, an inability to make decisions, and falling
asleep at the wheel of a motor vehicle. Those with mod-
erate to severe cases of the disorder are at a higher risk of
having a motor vehicle accident and may also have diffi-
culties at work or school [26].
Another prominent component of PSQI was use of
sleep medication. Despite the high incidence of sleep
disturbance in AS patients, they rarely use hypnotics.
The main reasons for impairment of chronic sleep dis-
turbance were not paid attention to by patients, such as
daytime sleepiness, fatigue, negative mood, and recogni-
tion [8-13]. Moreover, patients worry that long-term use
of sleep medication could increase the risks of develop-
ment of tolerance and dependence. Intervention for and
prevention of sleep disturbances are becoming increas-
ingly important. Recent studies [27,28] concluded that
nonpharmacologic interventions are clinically effective
for sleep disturbance, including sleep-hygiene education,
bright-light therapy, and cognitive and behavioral
therapies.
Sleep and pain
Pain is one of the most common symptoms of AS.
However, it is a chicken-and-egg problem to determine
the direction of causation between pain and sleep dis-
turbance. Some studies [29-31] demonstrated an appar-
ent bidirectionality in the relation between pain causing
sleep dysfunction and sleep dysfunction aggravating
pain. This cross-sectional study demonstrates a strong
association between not only sleep disturbance and pain
(nocturnal pain, total back pain), but also the compo-
nents of PSQI (subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep disorders,
use of sleep medications, daytime dysfunction) and pain
in AS patients.
These findings are consistent with a previous study
[32] showing an association between sleep disturbance
and clinical pain severity among RA patients. The
mechanism of interaction between sleep disturbance and
pain, so far not determined, could be understood with
two factors. First, from the perspective of neurobiology,
sleep disruption, fragmentation, or restriction produces
hyperalgesia and can interfere with analgesic treatments
involving opioidergic and serotonergic mechanisms of
action [33-36]. Second, from the perspective of psychol-
ogy, sleep disturbance lowers the pain threshold and
amplifies the pain signals, resulting in increased atten-
tion to pain, and more negative pain-focused emotions
and cognitions [3]. Thus, patients experience increased
pain by hyperalgesia, reduced activity levels, and further
disrupted sleep in a positive-feedback-loop pattern.
Sleep and disease activity
A close relation exists between sleep quality and disease
activity in AS patients. In the current study, analyses
were performed between patients who were good and
poor sleepers; poor-sleep patients had significantly higher
levels of morning stiffness, BASDAI, ESR, and CRP com-
pared with good sleepers (P < 0.05). These findings indi-
cate that sleep quality of AS patients is closely related to
disease activity. CRP could directly and/or indirectly
affect sleep quality. Some evidence [37-40] stems from
studies that indicate that poor sleep is associated with
inflammatory responses, indicated by increased CRP.
Okun et al. [40] evaluated cross-sectional relations
between self-reported sleep and three inflammatory mar-
kers (interleukin-6, tumor necrosis factor-a, and CRP) in
community-dwelling nonpregnant women. Findings
showed that poor sleep continuity and quality were
related to high levels of CRP. Furthermore, Lee et al. [2]
examining the association between disease activity, sleep,
and pain sensitivity in rheumatoid arthritis, found that
CRP was strongly associated with the pain threshold.
Speculating from this result, we suspect that the CRP
could indirectly affect sleep quality via a decreased pain
threshold.
Tumor necrosis factor (TNF) plays an important role
in AS and sleep regulation. Several observations [41,42]
strongly implicated TNF in the pathogenesis of AS, and
elevated serum levels of TNF correlate with disease
activity [43]. TNF-inhibitor therapies, such as thalido-
mide [44], etanercept [45], and infliximab [46], have
Table 7 Stepwise multiple regression analysis of demographic, physiological, medical, and psychological variables in
relation to PSQI
Independent B Standardized coefficients t P R2(%)
Predictors 39.5
SDS 0.059 0.170 2.884 0.004
SAS 0.128 0.287 4.759 0.000
Nocturnal pain (VAS) 0.235 0.191 2.511 0.013
Total back pain (VAS) 0.210 0.157 2.027 0.044
PSQI, Pittsburgh Sleep Quality Index; SAS, Self-rating Anxiety Scale; SDS, Self-rating Depression Scale, VAS, visual analogue scale.
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been demonstrated to be effective in the treatment of
AS. Moreover, TNF-a has been determined to be an
important sleep-promoting substance [47,48]. Chen-
naoui et al. [47] reported that total sleep deprivation in
young healthy men is associated with significant sleepi-
ness, decrements in psychomotor performance, and
increased secretion of the proinflammatory cytokine
TNF-a. The similar results of sleep deprivation led to
elevated levels of TNF-a had been obtained in another
experiment [48]. In turn, many of the symptoms
induced by sleep loss (for example, sleepiness, fatigue,
poor cognition, and enhanced sensitivity to pain) can be
elicited by injection of exogenous IL-1 or TNF [49].
Further study was done recently by Rudwaleit et al.
[50], and the results indicated that the TNF inhibitor,
adalimumab, improved sleep and sleep quality in
patients with active AS.
Sleep and depression
Sleep problems were the chief complaints of depression
and anxiety; early awakening is the main disturbance of
a depression disorder; and difficulty falling asleep is pre-
sent in anxiety disorder. In the present study, analyses
were performed between patients who were good and
poor sleepers. Poor-sleep patients had significantly
higher levels of SDS scores compared with good
sleepers.
Sleep disturbances in relation to a depressed mood
have been examined in the general population. Sayar et
al. [51] reported that pain intensity, anxiety, and depres-
sion correlated significantly with poorer sleep quality. At
the multivariate level, depression was found to be the
only significant factor correlating with the quality of
sleep, and the model explained 34% of the variance. In
2005, Costa et al. [52] compared systemic lupus erythe-
matosus patients with healthy controls and insomniacs
and concluded that only depressed mood was a signifi-
cant independent determinant of global sleep quality.
The relation between sleep complaints and depressed
mood is consistent with findings from another study of
SLE [4]. Hultgren et al. [19] reported that depression was
independently associated with three of the sleep para-
meters (quality, duration, and efficiency), whereas per-
ceived stress contributed to global sleep quality. In this
study, the association between depression and sleep distur-
bances was evident and significant on bivariate analysis,
but did not remain significant on logistic regression
analyses.
Sleep and anxiety
To our knowledge, this is the first study to examine anxi-
ety correlates of sleep problems in AS. Poor-sleep
patients had significantly higher levels of SAS scores
compared with those of good sleepers. Bivariate analyses
indicated a significant relation between anxiety and sleep
disturbances. The relation of sleep and anxiety, rarely has
been studied separately, apparently less than that of sleep
and depression. A number of studies [53-55] indicated
that sleep problems usually were associated with depres-
sion and anxiety. However, anxiety was divided into trait-
anxiety and state-anxiety in a study by Augner [56], who
reported that subjective sleep quality was strongly nega-
tively correlated with trait-anxiety, which is ingrained in
a person’s personality. Further study might indicate
whether state-anxiety, characterized as a temporary
change in a person’s emotional state due to an outside
factor, is correlated with sleep quality.
Statistical contribution in predicting sleep disturbances
A number of studies [13,57-60] indicated that poor sleep
or insomnia or both are risk factors for major depression.
Gregory et al. [57] reported that sleep problems predict
symptoms of depression at 10 years. Riemann et al. [59]
also reported that insomnia symptoms for a period of
more than 2 weeks predict an increased risk for develop-
ing depression within the following 3 years. A few studies
[13,60,61], usually included in surveys of sleep and depres-
sion, found that poor sleep or insomnia could predict
anxiety. In turn, little research exists on the role of depres-
sion and/or anxiety in sleep disturbances. In our hierarchic
multiple regression analysis, the medical and psychological
variables contributed significantly to the variance in sleep-
disturbances scores, adding an additional 23.9% to the
overall R2 beyond that accounted for by demographic vari-
ables (R2, 8.5%), resulting in a final R2of 42.6%. Multiple
stepwise regression analysis revealed that anxiety was the
maximal statistical contribution in predicting sleep distur-
bances. It is worth mentioning that Jansson and Lindblom
[11] conducted a population-based study providing pro-
spective evidence that individuals liable to anxiety may be
at particularly high risk of postevent sleep disturbances, at
least during the first months after the event.
Conclusions
In summary, half of the patients with AS are reported to
have sleep disturbances, and multidimensional assess-
ments have provided better understanding for the specific
aspects of sleep. The factors that contributed to poor sleep
in the study were overall assessment of health, pain, dis-
ease activity, BASFI, depression, and anxiety, even though
it was observed that anxiety was the maximal statistical
contribution in predicting sleep disturbances. Sleep dys-
function is importantly related to AS physical and psycho-
logical symptoms and deserves more attention in both
research and clinical practice. Results highlight the high
co-occurrence of sleep and AS problems, emphasizing the
need for assessment and intervention of sleep disturbance
in this population.
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